Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference



Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that Dr. Paul Liknaitzky, Head of Clinical Psychedelic Research at Monash University and Chief Principal Investigator for Incannex’s psilocybin-assisted psychotherapy, will present an overview of progress achieved in Incannex’s psychedelic medicine program at the H.C. Wainwright First Annual Mental Health Conference, taking place June 27, 2022Joel Latham, Managing Director and Chief Executive Officer of Incannex, will host virtual meetings with institutional investors during the conference.

The on-demand presentation will be available for viewing beginning at 7:00 a.m. U.S. EDT on June 27, 2022. A webcast of the presentation will be available on Incannex’s website at: and will be archived for a period of 90 days following the event.

This announcement has been approved for release to ASX by the Incannex board of directors.


Please enter your comment!
Please enter your name here